|Title:||Screening assays for compounds that inhibit membrane fusion-associated events|
|Abstract:||The present invention relates to peptides which exhibit potent anti-retroviral activity. The peptides of the invention comprise DP178 (SEQ ID:1) peptide corresponding to amino acids 638 to 673 of the HIV-1.sub.LAI gp41 protein, and fragments, analogs and homologs of DP178. The invention further relates to the uses of such peptides as inhibitory of human and non-human retroviral, especially HIV, transmission to uninfected cells.|
|Inventor(s):||Barney; Shawn O'Lin (Cary, NC), Lambert; Dennis Michael (Cary, NC), Petteway, Jr.; Stephen Robert (Cary, NC)|
|Assignee:||Trimeris, Inc. (Durham, NC)|
|Filing Date:||Sep 26, 1997|
|Claims:||1. A method for identifying peptides that inhibit membrane fusion events comprising: |
(a) the use of a ALLMOTI5, 107.times.178.times.4 or PLZIP computer search motif to identify peptides involved in coiled-coil peptide structures; and
(b) determining whether the identified peptides inhibit cell fusion.